PTC stock is in focus after the company joined Rambam Health Care Campus and EOS GmbH to build a Digital Implant Engineering Center in Haifa, Israel, using 3D printing and PTC's Creo CAD software. The collaboration news comes after a mixed stretch for PTC's stock, with a 1-day share price return of 4.84% but a year-to-date share price decline of 30.32%, and a 1-year total shareholder return down 42.05%. PTC's most followed valuation narrative places fair value at $179.25, well above the recent $118.52 close, suggesting the stock is 34% undervalued. The transition to SaaS and subscription-based models is generating more predictable, recurring revenues and is expected to deliver natural operating leverage, with non-GAAP operating expenses growing at half the rate of ARR, which should allow free cash flow growth to outpace ARR growth and eventually increase operating margins.
PTC IncPTC's Creo CAD software used in new 3D printing collaboration center.